Table 2. Study inclusion and exclusion criteria.

Inclusion criteria	Exclusion criteria
1. At least 18 years of age	1. Previous use of any PCSK9i
2. Very high-risk ASCVD	2. Uncontrolled hypertension (SBP ≥180 mmHg; DBP ≥110 mmHg) or diabetes
3. Have a qualifying LDL-C level at the time of screening based on the use of either no statin (LDL-C ≥3.4 mmol/L) or low or moderate intensity statin (LDL-C ≥1.8 mmol/L)	3. Known allergy or contraindication to evolocumab or atorvastatin
4. Successful PCI procedure	4. Known history of hemorrhagic stroke
5. OCT detected TCFA (TCFA is defined as FCT <65 mm and lipid radian greater than or equal to 2 quadrants)	5. Undergoing cancer treatment
	6. Treated with lipoprotein monocollection of blood components
	7. Severe liver and kidney dysfunction
	8. Pregnant or lactating women
	9. For any reason, the investigator considered patients who were not suitable for this study

PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor; ASCVD, atherosclerotic cardiovascular disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL-C, low-density lipoprotein cholesterol; PCI, percutaneous coronary intervention; OCT, optical coherence tomography; TCFA, thin-cap fibroatheroma; FCT, fibrous cap thickness.